AKBA
$1.49
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Intraday
Recent News
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock?
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference
Akebia Therapeutics (NASDAQ:AKBA) executives outlined the company’s near- and mid-term priorities at the Leerink Partners Global Healthcare Conference, emphasizing the commercialization of its anemia drug Vafseo, continued investment in kidney-disease programs, and smaller exploratory efforts outsid
How The Akebia Therapeutics (AKBA) Story Is Shifting As Vafseo Revenue Assumptions Reset
Akebia Therapeutics is back in focus after analysts trimmed their fair value estimate from US$5.00 to US$4.40, aligning with updated price targets clustered around US$4.00. These moves reflect how research desks are digesting the new US Renal Care dosing protocol and the related US$4.5m to US$5.0m inventory reduction that shaped reported Vafseo revenue in Q4. As you read on, you will see how these shifting targets and the debate around them can help you track the evolving story around this...
Akebia Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Akebia Therapeutics, Inc.'s Q4 2025 earnings call
Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Akebia Therapeutics Inc (AKBA) reports significant revenue growth driven by Vafseo and Auryxia, while navigating market challenges and preparing for future expansion.